Certain molecular lesions are inherently targetable in acute lymphoblastic leukemia (ALL); patients with these changes should be given access to therapy that specifically targets these lesions. Speaking from the 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL, Bijal Shah, MD, of the H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses how clinicians should be utilizing molecular data to improve treatment, giving a case-based example to poignantly highlight his point.
How should we utilizing molecular data to improve ALL treatment?
